Published in final edited form as:

Pharmacol Biochem Behav. 2011 December ; 100(2): 264–270. doi:10.1016/j.pbb.2011.08.026.

Oral and transdermal *dl*-methylphenidate – ethanol interactions in C57BL/6J mice: Potentiation of locomotor activity with oral delivery

Guinevere H. Bell¹, William C. Griffin III², and Kennerly S. Patrick¹

¹Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, SC

²Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

Abstract

Purpose—Many abusers of *dl*-methylphenidate co-abuse ethanol. The present animal study examined behavioral effects of oral or transdermal *dl*-methylphenidate in combination with a high, depressive dose of ethanol to model co-abuse.

Methods—Locomotor activity of C57BL/6J mice was recorded for 3 h following dosing with either oral *dl*-methylphenidate (7.5 mg/kg) or transdermal *dl*-methylphenidate (Daytrana®; ¼ of a 12.5 cm² patch; mean dose 7.5 mg/kg), with or without oral ethanol (3 g/kg). Brains were enantiospecifically analyzed for the isomers of methylphenidate and the transesterification metabolite ethylphenidate.

Results—An otherwise depressive dose of ethanol significantly potentiated oral *dl*-methylphenidate induced increases in total distance traveled for the first 100 min ($p < 0.05$). Transdermal *dl*-methylphenidate increased total distance traveled after a latency of 80 min, though this effect was not potentiated by concomitant ethanol. Mean 3 h brain *d*-methylphenidate concentrations were significantly elevated by ethanol in both the oral (65% increase) and transdermal (88% increase) groups. The corresponding *l*-ethylphenidate concentrations were 10 ng/g and 130 ng/g.

Conclusions—Stimulant induced motor activity in rodents may correlate with abuse liability. Potentiation of *dl*-methylphenidate motor effects by concomitant ethanol carries implications regarding increased abuse potential of *dl*-methylphenidate when combined with ethanol.

Keywords

methylphenidate; ethanol; ethylphenidate; locomotor activity; transdermal drug delivery

© 2011 Elsevier Inc. All rights reserved.

Please send correspondence to: Guinevere H. Bell, Ph.D., Department of Pharmaceutical and Biomedical Sciences, 280 Calhoun Street, Charleston SC 29425, 843-792-8429 ghb2@musc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. INTRODUCTION

The persistent of attention-deficit/hyperactivity disorder (ADHD) into adulthood has been increasingly recognized over the past few decades (Kessler et al. 2005; Okie 2006). In a survey, 92% of adult ADHD patients prescribed *dl*-methylphenidate (MPH) reported concomitant use of ethanol. Further, 100% of individuals who obtained *dl*-MPH through diversion co-abuse ethanol (Darredeau et al. 2007). The abuse potential of the *dl*-MPH – ethanol combination is well known in the clinical literature (Jaffe 1991; Barrett and Pihl 2002; Teter et al. 2003).

Coadministration of *dl*-MPH and ethanol results in pharmacokinetic and pharmacodynamic drug – drug interactions in humans (Patrick et al. 2007) and in C57BL/6J (C57) mice (Griffin et al. 2010; Bell et al. 2011). Ethanol elevates biological concentrations of the pharmacologically active *d*-MPH isomer and yields the metabolic transesterification product ethylphenidate (EPH) (Patrick et al. 2007; Bell et al. 2011). EPH appears to be formed through the actions of carboxylesterase 1 (CES1) (Bourland et al. 1997; Patrick et al. 2007) which exhibits *l*-MPH substrate enantioselectivity in both the metabolic transesterification and deesterification pathways (Sun et al. 2004; Williard et al. 2007; Zhu et al. 2008) (Figure 1). Accordingly, the mean absolute oral bioavailability of *l*-MPH is limited to only 1–3% compared to approximately 30% for *d*-MPH (Srinivas et al. 1993). However, dosing with transdermal *dl*-MPH (Daytrana®) avoids the extensive oral presystemic metabolism and leads to approximately 50 times more *l*-MPH reaching the systemic circulation when compared with oral dosing (Patrick et al. 2009).

The pharmacological significance of dosing route dependent alterations in the relative bioavailability of *d*-MPH versus *l*-MPH was investigated in the present study using a C57 mouse model in the context of ethanol interactions. The C57 mouse has served as a common reference strain in pre-clinical investigations of psychotropic agents, including the study of *dl*-MPH - ethanol interactions (Williard et al. 2007; Griffin et al. 2010; Bell et al. 2011), as well as for the behavioral characterization of EPH enantiomers (Patrick et al. 2005; Williard et al. 2007). As with humans, C57 mice enantioselectively transesterify *l*-MPH to *l*-EPH (Williard et al. 2007; Bell et al. 2011) (Figure 1) as well as exhibit a biphasic excitatory-to-depressant activity profile in response to increasing doses of ethanol (Phillips and Shen 1996).

A relatively low intraperitoneal (i.p.) dose of ethanol (1.75 g/kg) has been shown to elevate motor activity for 10–15 min in C57 mice (Griffin et al. 2010). However, when this dose of ethanol was combined with a sub-stimulatory dose of *dl*-MPH (1.25 mg/kg, i.p.), a potentiation of ethanol induced motor activity occurs. As an extension of this low dose *dl*-MPH - ethanol behavioral study (Griffin et al. 2010), and a C57 mouse dispositional investigation where ethanol was found to elevate blood, brain and urinary *d*-MPH (Bell et al. 2011), the following investigation examined the pharmacology of a high, otherwise motor depressive dose of ethanol, combined with a high stimulant dose of oral or transdermal *dl*-MPH. Locomotor activity counts were acquired for 3 h followed by enantiospecific MPH and EPH brain analysis.

The influence of ethanol on the stimulant effects of *dl*-MPH carries special abuse potential and adverse event liability for patients prescribed *dl*-MPH to treat ADHD, as well as for individuals obtaining *dl*-MPH through diversion.

2. MATERIALS AND METHODS

2.1 Materials

Ethanol was from AAPER Alcohol and Chemical Co. (Shelbyville, KY; 95%). *dl*-MPH•HCl used for oral animal studies was from Sigma-Aldrich (St. Louis, MO; lot # 118K1052) and 12.5 cm² transdermal *dl*-MPH patches (Daytrana[®]) were from Shire US (Wayne, PA; lot # 2616811; smallest of 4 sizes available). Laboratory tape used to secure transdermal *dl*-MPH or placebo patch (cut Band-Aid[®] adhesive which closely resembles the texture, adhesion and thickness of the *dl*-MPH patch) was from VWR International (white, 12.7 mm). *dl*-MPH•HCl in methanol (1 mg/mL calculated as free base; Cerilliant, Round Rock, TX) and *dl*-EPH•HCl in ethanol (1 mg/mL calculated as free base, synthesized in-house (Patrick et al. 2005)) were used as the analytical reference standards. Sodium carbonate (Fischer Scientific, Fair Lawn, NJ), *n*-butyl chloride (Burdick & Jackson, Muskegon, MI), acetonitrile (Mallinckrodt Inc, Paris, KT), (*S*)-*N*-(trifluoroacetyl)prolyl choride in dichloromethane (1M; Sigma- Aldrich, St Louis, MO), were used for extraction and chiral derivatization. Piperidine deuterated *dl*-MPH•HCl was synthesized in-house (Patrick et al. 1982) and contained approximately 25% of the D₅-isotopolog for SIM monitoring and containing no D₀₋₁-MPH.

2.2 Animals

Male C57 mice aged 8–10 weeks (25–35 g) were obtained from Jackson Laboratories (Bar Harbor, Maine, USA). They were individually housed in a temperature and humidity controlled colony room on a 12 h light/dark cycle (light: 07.00–19.00 h) with free access to food and water. All experiments were approved by and conducted within the guidelines of the Institutional Animal Care and Use Committee at the Medical University of South Carolina and followed the guidelines of the NIH Guide for the Care and Use of Laboratory Animals (NIH Publication no. 80–23, revised 1996).

2.3 Locomotor Activity and Analysis

2.3.1 Apparatus—Motor activity was assessed with a Digiscan Animal Activity Monitor system, model RXYZCM(8) TAO with a two-animal option (Omnitech Electronics, Columbus, Ohio, USA). Each activity chamber contained 2 arrays of 16 photo beams spaced 5 cm apart, with eight beams located on the x-axis and eight on the y-axis. One array was located 1.5 cm above floor level to capture horizontal activity and the other was located 6.5 cm above the floor to capture vertical activity of the mice. Stereotypic counts were recorded when the same beam was repeatedly interrupted. Photocells were activated when the photo beams on the wall directly opposite to the cells were interrupted. The Versadat analyzer (Version 2.70–137E) recorded the interruption of each beam and provided the total distance (cm) and vertical activity for each animal during testing. Each activity chamber was partitioned into 20 × 20 cm quadrants with acrylic dividers to allow simultaneous testing of two mice. Four activity chambers allowed testing of eight mice per session. Each of the activity chambers were enclosed in 90 × 54 × 35 cm sound-attenuated boxes.

2.3.2 Procedures for locomotor activity assessment—On days 1–3, mice were habituated to the motor activity apparatus for 30 min. On day 4 mice were lightly anesthetized with 5% isoflurane for 8–10 min. The hair was clipped with an electric shaver along the abdomen and back, from shoulders to hips. A placebo patch was placed on the lower left hip and secured by laboratory tape over the patch and around the mouse for one full loop to ensure a constant skin interface and to prevent the mice from disturbing the patch. Mice were then gavaged at a volume of 0.02 mL/g body weight with deionized water (dH₂O) and placed in the open-field activity chambers for 3 h. On Day 5, mice were randomly placed into 1 of 6 test groups (all with n = 8): placebo patch + dH₂O, placebo

patch + ethanol, placebo patch + oral *dl*-MPH + dH₂O, placebo patch + oral *dl*-MPH + ethanol, transdermal *dl*-MPH + dH₂O, or transdermal *dl*-MPH + ethanol. Oral *dl*-MPH was dosed as the HCl salt using 7.5 mg/kg calculated as the free base. This dose was the mean dose absorbed by ¼ patch as established by drug load difference between an unused versus used mouse patch study (Bell et al. 2011). Each animal was anesthetized and either a placebo patch or ¼ of 12 cm² transdermal patch was placed around the midsection in the same manner as day 4. They were gavaged at a volume of 0.02 mL/g body weight with either dH₂O or ethanol (3.0 g/kg) and placed in the activity apparatus for 3 h. Following the conclusion of the locomotor activity session, animals were sacrificed and brain samples collected.

The order of treatment groups within each week, and the particular test chamber used to test the different groups was counterbalanced across the entire experiment to eliminate any contribution of possible differences in activity monitors or days of testing to observed effects on motor activity. Total distance and vertical activity were recorded in 5-min bins for the entire 3 h session.

2.3.3 Locomotor Activity Data Analysis—Locomotor activity data in Figures 2 and 3 was grouped into 20 bins and analyzed using a mixed factor three-way analysis of variance (ANOVA). Oral *dl*-MPH data and transdermal *dl*-MPH data were analyzed separately using a 2(*dl*-MPH dose) × 2(ethanol dose) × 9(TimeBin) design. The between groups factors are *dl*-MPH (dH₂O vs. active dose) and ethanol (dH₂O vs. active dose). The repeated measure is TimeBin. When appropriate, post-hoc comparisons of significant main effects or factor interactions were made using pair-wise comparisons with Bonferroni's correction. Statistical analysis was conducted using PASW Statistics 18 (SPSS Inc., Chicago, Illinois, USA).

2.4 Brain MPH and EPH analysis

Enantiospecific analysis of *d*-, *l*-MPH and *d*-, *l*-EPH was conducted as previously described in a recent *dl*-MPH – ethanol disposition report (Bell et al. 2011). Briefly, homogenized and alkalized 1/2 brains were solvent extracted and after chiral derivatization, the samples were injected into a gas chromatograph – mass spectrometer fit with a 5% phenylmethylpolysiloxane column. The trifluoropropylpiperidyl electron impact fragment ions from analytes and the deuterated *dl*-MPH internal standard were acquired using selected ion monitoring. A range of spiked blank brain calibrators bracketed all concentrations reported as established by linear regression analysis ($r^2 > 0.99$).

2.4.1 Brain Concentration Data Analysis—A two way analysis of variance (ANOVA) followed by pair wise comparisons using the Student's t-test method was used in the analysis of all data. Samples were analyzed as independent samples and were assumed to have equal variances. Statistical analysis was conducted using SPSS 12.0 (SPSS I.; Chicago, Illinois, USA).

3. RESULTS

3.1 Controls

Mice treated with placebo patches + ethanol (3.0 g/kg) showed significantly less total distance traveled compared to mice treated with placebo patch + dH₂O over the first 100 min (all $ps < 0.05$) and significantly less vertical activity for the entire 3 h (all $ps < 0.01$).

3.2 Total Distance Traveled

3.2.1 Oral *dl*-MPH—The total distance traveled data was analyzed by examining changes in horizontal activity across time for the different treatment groups and is summarized in

Figure 2A. A significant 3 way interaction was found ($F(8,224)=10.906$, $p<0.001$). Post-hoc analysis indicated a significant increase in total distance traveled for oral *dl*-MPH + dH₂O compared to the placebo patch + dH₂O for the first 1 h (all $ps<0.05$). Further, total distance traveled for the oral *dl*-MPH + ethanol group was significantly greater than oral *dl*-MPH + dH₂O group over the first 100 min (all $ps<0.05$).

3.2.2 Transdermal dl-MPH—The total distance traveled data was analyzed by examining changes in horizontal activity across time for the different treatment groups and are summarized in Figure 3A. The 3 way interaction was not significant for the transdermal *dl*-MPH group. However, the lower level 2 way interactions were significant for TimeBin vs. ethanol ($F(8,224)=5.27$, $p<0.001$) and TimeBin vs. *dl*-MPH ($F(8,224)=28.07$, $p<0.001$). Post hoc analysis indicated a significant increase in total distance traveled for the transdermal *dl*-MPH + dH₂O group compared to the placebo patch + dH₂O group over the 100–180 min time period (all $ps<0.01$).

3.3 Vertical Activity

3.3.1 Oral dl-MPH—The vertical activity data was analyzed by examining changes in activity across time for the different treatment groups and is summarized in Figure 2B. A significant 3 way interaction was found ($F(8,224)=207.747$, $p<0.001$). Post-hoc analysis indicated a significant increase in vertical activity for oral *dl*-MPH + dH₂O compared to the placebo patch + dH₂O for the first 100 min (all $ps<0.05$). Vertical activity data for mice dosed with oral *dl*-MPH + ethanol and mice dosed with placebo patch + ethanol were significantly decreased compared to the placebo patch + dH₂O and oral *dl*-MPH + dH₂O for the entire 3 h (all $ps<0.001$).

3.3.2 Transdermal dl-MPH—The vertical activity data was analyzed by examining changes in activity across time for the different treatment groups and is summarized in Figure 3B. A significant 3 way interaction was found ($F(8,224)=34.935$, $p<0.001$). Post-hoc analysis indicated a significant increase in vertical activity for transdermal *dl*-MPH + dH₂O compared to the placebo patch + dH₂O 100–180 min (all $ps<0.01$). Vertical activity data for mice dosed with transdermal *dl*-MPH + ethanol and mice treated with placebo patch + ethanol were significantly decreased compared to placebo the patch + dH₂O and transdermal *dl*-MPH + dH₂O groups for the entire 3 h (all $ps<0.001$).

3.4 Brain Drug and Metabolite Concentrations

Oral dl-MPH—The brain concentration of *d*-MPH following oral *dl*-MPH was significantly greater in the animals dosed with ethanol compared to those given dH₂O; increasing from 31 ng/g to 51 ng/g (Figure 4A; $t=3.92$, $df=14$, $p<0.001$). Further, in animals dosed with oral *dl*-MPH, concentrations of *l*-MPH were significantly increased from 33 ng/g for animals dosed with dH₂O to 42 ng/g for animals dosed with concomitant ethanol (Figure 4A; $t=2.24$, $df=14$, $p<0.05$). There were no significant differences between the brain concentrations of *d*-MPH and *l*-MPH in animals dosed with dH₂O or in animals dosed with ethanol. Only the *l*-isomer of MPH was detected in animals gavaged with ethanol and was found at a concentration of 10 ng/g (Figure 4A).

Transdermal dl-MPH—The brain concentration of *d*-MPH after transdermal dosing was significantly greater in animals dosed with ethanol compared the dH₂O group; increasing from 689 ng/g to 1,294 ng/g (Figure 4B; $t=7.38$, $df=14$, $p<0.001$). Further, in animals dosed with transdermal *dl*-MPH, concentrations of *l*-MPH were significantly increased by ethanol, rising from 685 ng/g for animals dosed with dH₂O to 1,210 ng/g for animals dosed with ethanol (Figure 4B; $t=7.689$, $df=14$, $p<0.001$). There were no significant differences between the brain concentration of *d*-MPH and *l*-MPH in animals dosed with dH₂O, nor in

animals dosed with ethanol. Only the *l*-isomer of EPH was detected in animals gavaged with ethanol and was found at a mean concentration of 130 ng/g (Figure 4B).

4. Discussion

Most oral *dl*-MPH abusers coabuse ethanol (Darredeau et al. 2007) and the abuse potential of the *dl*-MPH – ethanol combination is well known in the clinical literature (Jaffe 1991; Barrett and Pihl 2002; Teter et al. 2003). In the present study, C57 mice were used to model pharmacological characteristics of this drug combination to gain insight into the special appeal this drug combination has. The abuse potential of the new transdermal *dl*-MPH formulation has not been investigated in detail at this time. In industry trials, transdermal *dl*-MPH has been reported to produce mild euphoria upon application of 3 or 6 of the 25 cm² patches. With the 6-patch application group dysphoria was reported in 42% of the test subjects. It is noted that the FDA requested human testing by the contraindicated application of the patch to buccal mucosa. This tissue surface greatly accelerated *dl*-MPH absorption relative to the normal hip application. Rather than the mean 36% of the patch *dl*-MPH content being absorbed during the recommended 9 h wear, 50% was absorbed in 2 h attached in the mouth (see Patrick et al. 2009).

We have previously reported that a sub-stimulatory i.p. dose of *dl*-MPH in C57 mice potentiates the motor stimulation produced by a low dose of ethanol (Griffin et al. 2010). The present study used stimulatory oral or transdermal doses of *dl*-MPH (7.5 mg/kg), with or without a depressive dose of ethanol (3 g/kg) to model dosing route dependent behavioral and dispositional drug interactions as may pertain to both the treatment of adult ADHD patients who use or abuse ethanol and the co-abuse pharmacology of diverted *dl*-MPH and ethanol.

The findings in the present study demonstrate that even a depressive dose of ethanol potentiates a stimulatory dose of oral *dl*-MPH. This potentiation may result from both pharmacokinetic and pharmacodynamic interactions. The 7.5 mg/kg doses of *dl*-MPH used in the present study approaches the highest daily doses found in the medical drug abuse literature, e.g., approximately 10 mg/kg/day intranasally (Coetzee et al. 2002) or 29 mg/kg/day intravenously (AtLee 1972) based on 60 kg total body weight (actual weights were not reported). While these doses were reported as total daily doses and the dosing “regimen” undisclosed, the intranasal route and certainly the intravenous routes are expected to result in higher bioavailability than following oral dosing. For instance, only 19% of an oral *dl*-MPH dose reaches the systemic circulation in rats (Wargin et al. 1983) versus approximately 30% in humans (Chan et al. 1983). Further, a transdermal dose of *dl*-MPH is absorbed in a prolonged fashion analogous to a multiple dose regimen as the abusers above were likely to have used.

When comparing animal doses for potential human extrapolation, body surface area normalization approaches have attempted to indirectly compensate for interspecies physiological differences such as basal metabolic rates, blood volumes and other brain/body relationships. Accordingly, body surface area calculations show a 7.5 mg/kg dose of *dl*-MPH in mice extrapolating to a 0.6 mg/kg “equivalent dose” for a 60 kg adult (Reagan-Shaw et al. 2008). This would be well within the clinical guidelines for *dl*-MPH mg/kg dosing (Greenhill et al. 1996). In a previous *dl*-MPH-ethanol disposition study using C57 mice and the same dosing regimens as in the present study, the mean *d*-MPH blood concentrations at time of sacrifice were 18 ng/mL 3 h after the oral *dl*-MPH bolus dose, compared to 360 ng/mL following a 3.25 h transdermal patch wear time. The disparity between the oral versus transdermal *d*-MPH blood concentrations may be based on the rapid clearance of the oral *dl*-MPH bolus dose and the expected steady increase in blood

concentrations of *d*-MPH when administered by the transdermal route. In humans, a 0.3 mg/kg oral dose of *dl*-MPH attains a mean maximum *d*-MPH plasma concentration of 15 ng/ml in 2 h while a comparable maximum plasma *d*-MPH concentration occurs at 9 h for transdermal *dl*-MPH following the recommended 9 h wear time (see (Patrick et al. 2009).

The ethanol dose of 3 g/kg used in this study corresponds to 10 ounces of 80% vodka in a 70 kg human, well within the range of ethanol consumption associated with bingeing. The choice of a 3 g/kg dose allowed comparisons with the urinary metabolites, blood and brain concentrations of *dl*-MPH and *dl*-EPH found in the previous metabolism study (Bell et al. 2011). Further, this dose allowed us to indirectly gauge probable concentrations of ethanol over the course of the present behavioral studies through comparison with literature values in C57 mice. Haseba et al. (2007) found the peak ethanol concentration to be 322 mg% at 0.5 h, declining to approximately 35 mg% 3 h after oral dosing.

Ethanol has been shown to significantly increase the maximum plasma concentration and total exposure to *d*-MPH and *l*-MPH in humans (Patrick et al. 2007), as well as elevate *d*-MPH and *l*-MPH blood, brain and urine concentrations in the C57 mouse (Bell et al. 2011). The present brain *d*-MPH, *l*-MPH and *l*-EPH determinations are concordant with our earlier reported brain concentrations (Bell et al. 2011). At the 3 h sacrifice time, the mean *d*-MPH brain concentration was 23 times higher in the transdermal group than in the oral dosing group without ethanol. Upon co-administration of ethanol, there was an 88% elevation of *d*-MPH in the transdermal group and 66% elevation following oral *dl*-MPH at the 3 h time point.

At the pharmacodynamic level, the potentiation of *dl*-MPH induced behavioral effects may be based on the mutual influence of these drugs on dopamine, i.e., both *d*-MPH and ethanol have been reported to elevate synaptic dopamine levels. The therapeutic activity of the stimulant *dl*-MPH in the treatment of ADHD prominently involves the reuptake blockade of impulse released dopamine through binding to the dopamine transporter (Volkow et al. 1998). In our animal model of *dl*-MPH – ethanol co-abuse, the potentiation of stimulatory effects by concomitant ethanol is consistent with evidence that ethanol releases pre-synaptic dopamine (Tang et al. 2003; Ramachandra et al. 2007) as a consequence of upstream GABAergic signaling (Theile et al. 2011). Hence ethanol may be increasing extracellular dopamine release, whereby *d*-MPH then blocks a larger dopamine pool from presynaptic reuptake. Further, ethanol-mediated dopamine release significantly increases as the ethanol dose (i.p.) is escalated from 1 g/kg to 2 g/kg to 3 g/kg in C57 mice (Ramachandra et al. 2007); the 3 g/kg of ethanol corresponding to the oral dose used in the present study. In this context, we hypothesize that the increased locomotor activity resulting from concomitant oral *dl*-MPH and an otherwise depressive dose of ethanol may reflect a synergistic increase in synaptic dopamine, modeling the accentuation of likeability associated with *dl*-MPH combined with ethanol when compared to *dl*-MPH alone (Patrick et al. 2007).

In humans, the earliest detection of either MPH isomer in plasma after transdermal *dl*-MPH application ranges from 1–6 h (Shire. 2006. Revised 6/2010.), unlike oral *dl*-MPH which is readily detectable within 30 min or less (Modi et al. 2000; Zhu et al. 2011). The significantly lower total distance traveled of mice dosed with transdermal *dl*-MPH compared to oral *dl*-MPH is likely influenced by a lag phase (latency) in transdermal drug absorption during which time locomotor activity of mice inherently decreases as habituation to the activity chamber occurs. We report here that the lag phase between application of the transdermal *dl*-MPH patch and the onset of pronounced drug-induced motor activity is approximately 100 min in C57 mice. Studies in C57 mice have shown that *d*- and *dl*-MPH produce dose-related increases in motor activity, while the *l*-isomer produces little or no stimulatory effects (Williard et al. 2007). Thus, it is hypothesized that despite significantly higher 3 h brain

concentrations of *d*-MPH following transdermal dosing, the total distance traveled of mice did not reach the same levels of early time points following oral dosing due in part to the mice habituating to the chambers and such low activity was not able to rebound to early activity levels found after oral dosing. A further explanation for the attenuated total distance traveled by the transdermal *dl*-MPH – ethanol group could pertain to the induction of stereotypic behaviors associated with such high brain *d*-MPH concentrations, especially in the concomitant ethanol group. This may be supported by the significantly higher vertical activity found at later time points following transdermal dosing. Further, the observation that the stimulant effect of transdermal *dl*-MPH was not potentiated by co-administration of ethanol may relate to the anticipated lag phase in transdermal drug absorption extending well into the elimination phase of ethanol (see (Bell et al. 2011). It is noted that the mean elimination half-life of ethanol in C57 mice has been reported to be approximately 1.3 h to 1.5 h (Haseba et al. 2007; Ramachandra et al. 2007).

The 13-fold greater *l*-EPH concentration found in the transdermal *dl*-MPH – ethanol group relative to the oral *dl*-MPH – ethanol group is unlikely to directly contribute to the neuropharmacology of this drug combination in view of the inactivity of the *l*-isomer of EPH in vivo or in vitro (Patrick et al. 2005; Williard et al. 2007). However, the *l*-EPH concentration may indirectly gauge the extent to which *dl*-MPH and ethanol interact with CES1.

The presence of *l*-EPH in the C57 mouse brain samples offers further evidence that this transesterification metabolite can serve as a biomarker for concomitant *dl*-MPH – ethanol exposure (Markowitz et al. 1999). Most importantly, ethanol significantly potentiated oral *dl*-MPH induced stimulant effects and elevated the brain *d*-MPH concentrations in this C57 mouse model. These findings could carry implications for increased abuse liability when ethanol is combined with *dl*-MPH should this model generalize to humans.

Highlights

- > Locomotor activity of C57 mice was recorded for 3 h following dosing with either oral or transdermal *dl*-methylphenidate with or without oral ethanol (3 g/kg
- > An otherwise depressive dose of ethanol significantly potentiated oral *dl*-methylphenidate induced increases in total distance traveled for the first 100 min. Transdermal *dl*-methylphenidate increased total distance traveled after a latency of 80 min, though this effect was not potentiated by concomitant ethanol.
- > Potentiation of *dl*-methylphenidate motor effects by concomitant ethanol carries implications regarding increased abuse potential of *dl*-methylphenidate.

ABBREVIATIONS

ADHD	Attention-Deficit/Hyperactivity Disorder
C57	C57BL/6J
CES1	Carboxylesterase 1
dH₂O	Deionized water
EPH	Ethylphenidate

i.p. intraperitoneal
MPH Methylphenidate

Acknowledgments

This study was supported by the NIH RO1 AA016707 (KSP).

REFERENCES

- AtLee WE Jr. Talc and cornstarch emboli in eyes of drug abusers. *JAMA*. 1972; 219(1):49–51. [PubMed: 5066587]
- Barrett SP, Pihl RO. Oral methylphenidate-alcohol co-abuse. *J Clin Psychopharmacol*. 2002; 22(6): 633–634. [PubMed: 12454570]
- Bell GH, Novak AJ, et al. Transdermal and oral dl-methylphenidate - ethanol interactions in C57BL/6J mice: Transesterification to ethylphenidate with elevated d-methylphenidate concentrations. *Journal of Pharmaceutical Sciences*. 2011 (In Press).
- Bourland JA, Martin DK, et al. Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: preliminary in vitro findings using a rat liver preparation. *J Pharm Sci*. 1997; 86(12):1494–1496. [PubMed: 9423167]
- Chan YP, Swanson JM, et al. Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid. *Pediatrics*. 1983; 72(1):56–59. [PubMed: 6866592]
- Coetzee M, Kaminer Y, et al. Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder. *Subst Abus*. 2002; 23(3):165–169. [PubMed: 12444349]
- Darredeau C, Barrett SP, et al. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. *Hum Psychopharmacol*. 2007; 22(8):529–536. [PubMed: 17910020]
- Greenhill LL, Abikoff HB, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. *J Am Acad Child Adolesc Psychiatry*. 1996; 35(10):1304–1313. [PubMed: 8885584]
- Griffin WC 3rd, Novak AJ, et al. The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice. *Pharmacol Biochem Behav*. 2010; 95(3):267–272. [PubMed: 20122954]
- Haseba T, Mashimo K, et al. Maturation of whisky changes ethanol elimination kinetics and neural effects by increasing nonvolatile congeners. *Alcohol Clin Exp Res*. 2007; 31 Suppl(1):S77–S82. [PubMed: 17331171]
- Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. *J Am Acad Child Adolesc Psychiatry*. 1991; 30(5):773–775. [PubMed: 1938793]
- Kessler RC, Adler LA, et al. Patterns and predictors of attentiondeficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. *Biol Psychiatry*. 2005; 57(11):1442–1451. [PubMed: 15950019]
- Markowitz JS, Logan BK, et al. Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. *J Clin Psychopharmacol*. 1999; 19(4):362–366. [PubMed: 10440465]
- Modi NB, Lindemulder B, et al. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. *J Clin Pharmacol*. 2000; 40(4):379–388. [PubMed: 10761165]
- Okie S. ADHD in adults. *N Engl J Med*. 2006; 354(25):2637–2641. [PubMed: 16790695]
- Patrick K, Kilts C, et al. Synthesis of deuterium-labelled methylphenidate, p-hydroxymethylphenidate, ritalinic acid and p-hydroxyritalinic acid. *Journal of Labelled Compounds and Radiopharmaceuticals*. 1982; 19(4):485–490.

- Patrick KS, Straughn AB, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. *Clin Pharmacol Ther.* 2007; 81(3):346–353. [PubMed: 17339864]
- Patrick KS, Straughn AB, et al. Evolution of stimulants to treat ADHD: transdermal methylphenidate. *Hum Psychopharmacol.* 2009; 24(1):1–17. [PubMed: 19051222]
- Patrick KS, Williard RL, et al. Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol. *J Med Chem.* 2005; 48(8):2876–2881. [PubMed: 15828826]
- Phillips TJ, Shen EH. Neurochemical bases of locomotion and ethanol stimulant effects. *Int Rev Neurobiol.* 1996; 39:243–282. [PubMed: 8894850]
- Ramachandra V, Phuc S, et al. Ethanol preference is inversely correlated with ethanol-induced dopamine release in 2 substrains of C57BL/6 mice. *Alcohol Clin Exp Res.* 2007; 31(10):1669–1676. [PubMed: 17651469]
- Reagan-Shaw S, Nihal M, et al. Dose translation from animal to human studies revisited. *FASEB J.* 2008; 22(3):659–661. [PubMed: 17942826]
- Shire. Methylphenidate Percipibing Information. Wayne, PA: 2006.
- Srinivas NR, Hubbard JW, et al. Enantioselective pharmacokinetics of dl-threomethylphenidate in humans. *Pharm Res.* 1993; 10(1):14–21. [PubMed: 8430051]
- Sun Z, Murry DJ, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. *J Pharmacol Exp Ther.* 2004; 310(2):469–476. [PubMed: 15082749]
- Tang A, George MA, et al. Ethanol increases extracellular dopamine concentration in the ventral striatum in C57BL/6 mice. *Alcohol Clin Exp Res.* 2003; 27(7):1083–1089. [PubMed: 12878914]
- Teter CJ, McCabe SE, et al. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. *Pharmacotherapy.* 2003; 23(5):609–617. [PubMed: 12741435]
- Theile JW, Morikawa H, et al. GABAergic transmission modulates ethanol excitation of ventral tegmental area dopamine neurons. *Neuroscience.* 2011; 172:94–103. [PubMed: 20974231]
- Volkow ND, Wang GJ, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. *Am J Psychiatry.* 1998; 155(10):1325–1331. [PubMed: 9766762]
- Wargin W, Patrick K, et al. Pharmacokinetics of methylphenidate in man, rat and monkey. *J Pharmacol Exp Ther.* 1983; 226(2):382–386. [PubMed: 6410043]
- Williard RL, Middaugh LD, et al. Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. *Behav Pharmacol.* 2007; 18(1):39–51. [PubMed: 17218796]
- Zhu HJ, Patrick KS, et al. Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: Application to human ethanol interactions. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2011; 879(11–12):783–788.
- Zhu HJ, Patrick KS, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. *Am J Hum Genet.* 2008; 82(6):1241–1248. [PubMed: 18485328]

Figure 1.

Enantioselective de-esterification of *dl*-MPH to ritalinic acid (top right) and transesterification to *l*-ethylphenidate.

Figure 2.

(A) Oral *dl*-MPH + dH₂O significantly increased total distance traveled (*, $p < 0.05$) and this effect was potentiated by a depressive dose of ethanol (+, $p < 0.05$). (B) Oral *dl*-MPH significantly increased vertical activity of mice over the first 100 min (*, $p < 0.05$).

Figure 3.

(A) Transdermal *dl*-MPH induced locomotor activity after a lag phase of 100 min (**, $p < 0.01$). While this effect was not potentiated by ethanol, transdermal *dl*-MPH + ethanol was significantly greater than placebo patch + dH₂O after a lag phase of 140 min (++, $p < 0.01$). (B) Transdermal *dl*-MPH significantly increased vertical activity of mice after 100 min lag time (*, $p < 0.05$).

Figure 4.
(A&B) Ethanol significantly increased brain concentrations of *d*-MPH and *l*-MPH relative to dH₂O in mice dosed orally or transdermally (*, $p < 0.05$; ***, $p < 0.001$).